Overview

Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective,open-labelled,multi-center,randomized clincial trial.It comapres the clincal efficiacy and safety of there 2 drugs in the treatment of relapse active Takayasu's arteritis patients.
Phase:
Phase 4
Details
Lead Sponsor:
Chinese SLE Treatment And Research Group
Treatments:
Adalimumab